Arnaud Guillet
Vice-President, Business Development

Is this your profile?

About

Arnaud Guillet is Vice-President, Business Development at Biocorp, in charge of finding partnerships and license opportunities for Biocorp’s range of connected devices. Previously, Mr Guillet worked for a healthcare consulting firm with a strong focus on connected health strategies for pharma and insurance companies and has additional past experience in the pharmaceutical industry (with Sanofi) and the insurance industry (with AXA). He graduated from HEC Paris, a major European business school.

Contributions

Interview with Arnaud Guillet & Fanny Sellier

Arnaud Guillet and Fanny Sellier talk with Guy Furness about how Biocorp has become a key player in the field of connected drug delivery, discuss the current landscape for connectivity in drug delivery and update us on its two major parenteral products – Mallya and Injay – as well as looking forward to the launch of the company’s next generation of connected drug delivery solutions.

More contributions

Interview with Biocorp’s Arnaud Guillet

In this exclusive interview, Arnaud Guillet of Biocorp talks with ONdrugDelivery about connectivity in the injectables space, sharing some of the insights Biocorp has gained from its decade of experience in developing connected drug delivery devices.

Interview: Arnaud Guillet, Biocorp

In this exclusive interview with ONdrugDelivery, Arnaud Guillet discusses Mallya, Biocorp’s connected clip-on for pen injectors, including Mallya’s successful launch in multiple countries this year, the factors that have played into the device’s success, and the future for Mallya, Biocorp and connectivity in the drug delivery industry.

BIOCORP’S MALLYA – CHRONICLING A SUCCESS STORY

Arnaud Guillet and colleagues from across the industry, discuss Bicorp’s Mallya add-on device for disposable insulin pens, providing details on the main country launches and key software integrations, as well as presenting initial feedback from healthcare professionals and patients.

INJAY: SIMPLE BY CHOICE, ADAPTABLE BY DESIGN

Arnaud Guillet discusses Biocorp’s Injay solution for adding connectivity to a wide variety of PFS devices, focusing on how Injay’s designed-in simplicity and flexibility makes it easily applicable across the spectrum of PFS platforms on the market today.

MALLYA: ENLIGHTENING PAST, EXCITING PRESENT, PROMISING FUTURE

Arnaud Guillet reviews the Mallya connected device platform, from the origins of the project to the current success in diabetes and deployment in other fields, and introduces the promising next-generation Mallya.

MEASURING & MANAGING MEDICATION ADHERENCE FROM CLINICAL TRIALS TO ROUTINE CARE: INJAY MEMS AS^®

Arnaud Guillet and Bernard Vrijens discuss the issue of medication non-adherence in both clinical trials and commercialised drug products, and how Biocorp’s Injay connected prefilled syringe solution combined with Aardex’s MEMS Adherence Software provides a solution.

SENSORS ARE TOOLS – BUT HOW DO YOU MAKE THEM SMART?

Gaël Senée and Arnaud Guillet explore the benefits of Mallya – a smart sensor that turns conventional injection pens into connected devices. They also discuss the crucial role Biocorp’s connected prefilled syringe, Injay, could play in future COVID-19 vaccination programmes.

ADDING VALUE TO PREFILLED SYRINGES: SAFETY AND CONNECTIVITY

Chantal Wierckx and Arnaud Guillet provide an update on Newguard™, Biocorp’s integrated safety device for prefilled syringes, and explore the possible advantages connectivity can bring in the context of traceability for anti-counterfeiting, in clinical trials and in vaccination campaigns.

COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS

As Biocorp prepares for the market launch of its connected injector pen add-on, Mallya, Eric Dessertenne and Arnaud Guillet share insights about key steps in the company’s development. The article discusses the many partnership Biocorp has entered in to, and includes a mini-interview with Sergio Monti, Plant Manager for one such partner, V.A.R.I.

PREFILLED SYRINGES

A MODEL FOR TRANSFORMING BREAKTHROUGH INNOVATIONS IN SUCCESSFUL PRODUCTS

Eric Dessertenne, Philippe Lesaulnier and Arnaud Guillet outline Biocorp’s approach to device design and detail two products in the company’s portfolio, Newguard and Easylog, which are anticipated for market launch next year.

ARNAUD GUILLET, BIOCORP

Arnaud Guillet discusses Biocorp’s existing connected devices, value for pharmaceutical partners, accompanying software and data architecture and Biocorp's triple expertise in medical devices, electronics and software.

THE MULTIPLE VALUES OF INTEGRATED SOLUTIONS

Arnaud Guillet and Eric Dessertenne, both of Biocorp outline the potential value of the data that can be collected from integrated devices, not only for pharma companies but also for patients and payers.

Top